Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2009 Feb;70(1):35–54. doi: 10.1016/j.curtheres.2009.02.004

Varenicline for smoking cessation: A review of the literature

Kirandeep Kaur 1,a, Sandeep Kaushal 1, Sarvesh C Chopra 1
PMCID: PMC3969980  PMID: 24692831

Abstract

Background: Smoking is the leading preventable risk to human health. Various agents have been used to promote smoking cessation, but none has had long-term efficacy. Varenicline, a new nicotinic ligand based on the structure of cytosine, was approved by the US Food amd Drug Administration for use as a smoking cessation aid.

Objectives: The aims of this review were to provide an overview on the mechanism of action and preclinical and clinical data of the new drug, varenicline, and to discuss the current and future impact of varenicline as a treatment for smoking cessation.

Methods: MEDLINE, BIOSIS, and Google scholar databases were searched (March 1, 2007–July 1, 2008) using the terms varenicline, smoking cessation, and nicotinic receptors. Full-text articles in English were selected for reference, and articles presenting the mechanism of action, pharmacokinetics, and data from preclinical and clinical trials were included.

Results: The initial literature search yielded 70 papers. A total of 20 articles fulfilled the inclusion criteria. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, inhibits dopaminergic activation produced by smoking and decreases the craving and withdrawal syndrome that accompanies cessation attempts. In Phase III clinical trials, the carbon monoxide-confirmed 4-week continuous abstinence rates were significantly higher with varenicline than with buproprion sustained release or placebo for weeks 9 through 12. Varenicline has been found to be well tolerated, with nausea being the most commonly reported (28.1%) adverse event.

Conclusions: Varenicline is the first drug for smoking cessation that has been found to have significant effectiveness in long-term relapse prevention (up to 52 weeks). Varenicline, with its unique profile of agonist and antagonist properties, increased cessation rates (both short- and long-term) compared with both placebo and bupropion sustained release.

Key words: varenicline, smoking cessation, nicotinic receptors, review

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

References

  • 1.Centers for Disease Control and Prevention (CDC) Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. MMWR Morb Mortal Wkly Rep. 2005;54:625–628. [PubMed] [Google Scholar]
  • 2.O'Brien CP. Drug addiction and drug abuse. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. McGraw Hill; New York, NY: 2006. p. 615. [Google Scholar]
  • 3.Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: Past, present and future. Drug Alcohol Rev. 2006;25:59–71. doi: 10.1080/09595230500459529. [DOI] [PubMed] [Google Scholar]
  • 4.Jorenby DE, Hays JT, Rigotti NA, Varenicline Phase 3 Study Group Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial [published correction appears in JAMA. 2006;296:1355] JAMA. 2006;296:56–63. doi: 10.1001/jama.296.1.56. [DOI] [PubMed] [Google Scholar]
  • 5.Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55:281–299. doi: 10.3322/canjclin.55.5.281. [DOI] [PubMed] [Google Scholar]
  • 6.Warner C., Shoiab M. Vol. 10. 2005. How does bupropion work as a smoking cessation aid? pp. 219–231. (Addict Biol). [DOI] [PubMed] [Google Scholar]
  • 7.Hurt RD, Sachs DP, Glover ED. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202. doi: 10.1056/NEJM199710233371703. [DOI] [PubMed] [Google Scholar]
  • 8.Jorenby DE, Leischow SJ, Nides MA. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691. doi: 10.1056/NEJM199903043400903. [DOI] [PubMed] [Google Scholar]
  • 9.US Food and Drug Administration FDA Approves Novel Medication for Smoking Cessation. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01370.html Accessed August 15, 2008.
  • 10.Pfizer Labs Chantix®. http://www.pfizer.com/files/products/uspi_chantix.pdf Accessed August 15, 2008.
  • 11.Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 1996;16:905–908. doi: 10.1016/s0896-6273(00)80112-9. [DOI] [PubMed] [Google Scholar]
  • 12.Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000;25:515–532. doi: 10.1016/s0896-6273(00)81056-9. [DOI] [PubMed] [Google Scholar]
  • 13.Pidoplichko VI, Noguchi J, Areola OO. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learn Mem. 2004;11:60–69. doi: 10.1101/lm.70004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Balfour DJ, Wright AE, Benwell ME, Birrell CE. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res. 2000;113:73–83. doi: 10.1016/s0166-4328(00)00202-3. [DOI] [PubMed] [Google Scholar]
  • 15.Wu J, George AA, Schroeder KM. Electrophysiological, pharmacological, and molecular evidence for alpha7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. J Pharmacol Exp Ther. 2004;311:80–91. doi: 10.1124/jpet.104.070417. [DOI] [PubMed] [Google Scholar]
  • 16.Corrigall WA. Nicotine self-administration in animals as a dependence model. Nicotine Tob Res. 1999;1:11–20. doi: 10.1080/14622299050011121. [DOI] [PubMed] [Google Scholar]
  • 17.Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: Varenicline. Int J Clin Pract. 2006;60:571–576. doi: 10.1111/j.1368-5031.2006.00955.x. [DOI] [PubMed] [Google Scholar]
  • 18.Tutka P, Zatoński W. Cytisine for treatment of nicotine addiction: From a molecule to therapeutic efficacy. Pharmacol Rep. 2006;58:777–798. [PubMed] [Google Scholar]
  • 19.Etter JF. Cytisine for smoking cessation: A literature review and a meta-analysis. Arch Intern Med. 2006;166:1553–1559. doi: 10.1001/archinte.166.15.1553. [DOI] [PubMed] [Google Scholar]
  • 20.Coe JW, Brooks PR, Vetelino MG. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477. doi: 10.1021/jm050069n. [DOI] [PubMed] [Google Scholar]
  • 21.Steensland P, Simms JA, Holgate J. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA. 2007;104:12518–12523. doi: 10.1073/pnas.0705368104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rollema H, Chambers LK, Coe JW. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985–994. doi: 10.1016/j.neuropharm.2006.10.016. [DOI] [PubMed] [Google Scholar]
  • 23.Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70:801–805. doi: 10.1124/mol.106.025130. [DOI] [PubMed] [Google Scholar]
  • 24.McColl SL, Burstein AH, Reeves KR. Human abuse liability of the smoking cessation drug varenicline in the smokers and nonsmokers. Clin Pharmacol Ther. 2008;83:607–614. doi: 10.1038/sj.clpt.6100510. [DOI] [PubMed] [Google Scholar]
  • 25.Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci. 2001;21:1452–1463. doi: 10.1523/JNEUROSCI.21-05-01452.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Schilström B, Svensson HM, Svensson TH, Nomikos GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: Putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience. 1998;85:1005–1009. doi: 10.1016/s0306-4522(98)00114-6. [DOI] [PubMed] [Google Scholar]
  • 27.Obach RS, Reed-Hagen AE, Krueger SS. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121–130. doi: 10.1124/dmd.105.006767. [DOI] [PubMed] [Google Scholar]
  • 28.Faessel HM, Smith BJ, Gibbs MA. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol. 2006;46:991–998. doi: 10.1177/0091270006290669. [DOI] [PubMed] [Google Scholar]
  • 29.Faessel HM, Gibbs MA, Clark DJ. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006;46:1439–1448. doi: 10.1177/0091270006292624. [DOI] [PubMed] [Google Scholar]
  • 30.Zierler-Brown SL, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother. 2007;41:95–99. doi: 10.1345/aph.1H310. [DOI] [PubMed] [Google Scholar]
  • 31.Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol. 2006;46:1234–1240. doi: 10.1177/0091270006291837. [DOI] [PubMed] [Google Scholar]
  • 32.Oncken C, Gonzales D, Nides M. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571–1577. doi: 10.1001/archinte.166.15.1571. [DOI] [PubMed] [Google Scholar]
  • 33.Pfizer Inc. Chantix full prescribing information. http://www.chantix.com/content/Prescribing_Information.jsp Accessed July 22, 2008.
  • 34.Burstein AH, Clark DJ, O'Gorman M. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: An in vivo and in vitro study. J Clin Pharmacol. 2007;47:1421–1429. doi: 10.1177/0091270007307574. [DOI] [PubMed] [Google Scholar]
  • 35.Nides M, Oncken C, Gonzales D. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow up. Arch Intern Med. 2006;166:1561–1568. doi: 10.1001/archinte.166.15.1561. [DOI] [PubMed] [Google Scholar]
  • 36.Gonzales D, Rennard SI, Nides M, Varenicline Phase 3 Study Group Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006;296:47–55. doi: 10.1001/jama.296.1.47. [DOI] [PubMed] [Google Scholar]
  • 37.Tonstad S, Tønnesen P, Hajek P, Varenicline Phase 3 Study Group Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA. 2006;296:64–71. doi: 10.1001/jama.296.1.64. [DOI] [PubMed] [Google Scholar]
  • 38.Tsai ST, Cho HJ, Cheng HS. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29:1027–1039. doi: 10.1016/j.clinthera.2007.06.011. [DOI] [PubMed] [Google Scholar]
  • 39.Nakamura M, Oshima A, Fujimoto Y. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007;29:1040–1056. doi: 10.1016/j.clinthera.2007.06.012. [DOI] [PubMed] [Google Scholar]
  • 40.Aubin HJ, Bobak A, Britton JR. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomized open-label trial. Thorax. 2008;63:717–724. doi: 10.1136/thx.2007.090647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289–294. doi: 10.1001/archpsyc.1986.01800030107013. [DOI] [PubMed] [Google Scholar]
  • 42.Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSUbrief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7–16. doi: 10.1080/14622200020032051. [DOI] [PubMed] [Google Scholar]
  • 43.Cappelleri JC, Bushmakin AG, Baker CL. Confirmatory factor analyses and reliability of the modified cigarette evaluation quiestionnaire. Addict Behav. 2007;32:912–923. doi: 10.1016/j.addbeh.2006.06.028. [DOI] [PubMed] [Google Scholar]
  • 44.US Food and Drug Administration FDA Drug Safety Podcasts Varenicline (marked as Chantix) http://www.fda.gov/cder/drug/podcast/varenicline_full.htm Accessed August 15, 2008.
  • 45.Coleman T. Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs. 2007;21:983–993. doi: 10.2165/00023210-200721120-00003. [DOI] [PubMed] [Google Scholar]
  • 46.Tønnesen P, Tonstad S, Hjalmarson A. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med. 2003;254:184–192. doi: 10.1046/j.1365-2796.2003.01185.x. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES